Total Payments
$341,486
2024 Payments
$10,511
Companies
28
Transactions
283
Medicare Patients
879
Medicare Billing
$97,835
Payment Breakdown by Category
Consulting$229,126 (67.1%)
Other$59,634 (17.5%)
Travel$35,113 (10.3%)
Research$13,307 (3.9%)
Food & Beverage$4,090 (1.2%)
Education$217.55 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $229,126 | 71 | 67.1% |
| Travel and Lodging | $35,113 | 77 | 10.3% |
| Honoraria | $30,296 | 12 | 8.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $29,338 | 7 | 8.6% |
| Unspecified | $13,307 | 15 | 3.9% |
| Food and Beverage | $4,090 | 81 | 1.2% |
| Education | $217.55 | 20 | 0.1% |
Payments by Type
General
$328,179
268 transactions
Research
$13,307
15 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Sandoz Inc. | $40,376 | 22 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $36,029 | 18 | $0 (2022) |
| Merck Sharp & Dohme Corporation | $31,970 | 40 | $0 (2020) |
| PFIZER INC. | $31,155 | 36 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $28,224 | 22 | $0 (2023) |
| Samsung Bioepis Co., Ltd. | $25,602 | 14 | $0 (2023) |
| UCB, Inc. | $25,505 | 19 | $0 (2023) |
| Amgen Inc. | $19,679 | 16 | $0 (2024) |
| Boehringer Ingelheim Pharma GmbH & Co.KG | $13,343 | 9 | $0 (2017) |
| Celltrion Healthcare Co., Ltd | $12,908 | 6 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $10,511 | 5 | Hexal AG ($4,900) |
| 2023 | $47,022 | 26 | Samsung Bioepis Co., Ltd. ($16,364) |
| 2022 | $20,852 | 17 | Novartis Pharmaceuticals Corporation ($6,650) |
| 2021 | $17,344 | 8 | PFIZER INC. ($7,700) |
| 2020 | $34,061 | 22 | PFIZER INC. ($11,740) |
| 2019 | $54,506 | 45 | Novartis Pharmaceuticals Corporation ($13,712) |
| 2018 | $79,381 | 82 | Novartis Pharmaceuticals Corporation ($15,167) |
| 2017 | $77,810 | 78 | Boehringer Ingelheim Pharma GmbH & Co.KG ($13,343) |
All Payment Transactions
283 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/06/2024 | Organon Llc | HADLIMA (Drug) | Honoraria | Cash or cash equivalent | $695.00 | General |
| Category: ADALIMUMAB-BWWD | ||||||
| 06/24/2024 | Hexal AG | — | Consulting Fee | Cash or cash equivalent | $4,900.00 | General |
| 06/14/2024 | Lilly USA, LLC | TALTZ (Drug) | Food and Beverage | In-kind items and services | $25.09 | General |
| Category: Immunology | ||||||
| 03/04/2024 | Amgen Inc. | AMJEVITA (Biological) | — | In-kind items and services | $4,195.73 | Research |
| Study: RW TX patterns among patients treated with AMJEVITA in Germany and France. • Category: Inflammation | ||||||
| 01/03/2024 | Organon Llc | HADLIMA (Drug) | Honoraria | Cash or cash equivalent | $695.00 | General |
| Category: ADALIMUMAB-BWWD | ||||||
| 12/21/2023 | Samsung Bioepis Co., Ltd. | — | Consulting Fee | Cash or cash equivalent | $550.00 | General |
| 08/22/2023 | Sandoz Inc. | HYRIMOZ (Drug) | Consulting Fee | Cash or cash equivalent | $2,100.00 | General |
| Category: IMMUNOLOGY | ||||||
| 08/16/2023 | Fresenius Kabi USA, LLC | IDACIO (Biological) | Consulting Fee | Cash or cash equivalent | $5,400.00 | General |
| Category: Biosimilars | ||||||
| 08/16/2023 | Fresenius Kabi USA, LLC | IDACIO (Biological) | Consulting Fee | Cash or cash equivalent | $413.25 | General |
| Category: Biosimilars | ||||||
| 08/16/2023 | Fresenius Kabi USA, LLC | IDACIO (Biological) | Consulting Fee | Cash or cash equivalent | $74.15 | General |
| Category: Biosimilars | ||||||
| 08/16/2023 | Fresenius Kabi USA, LLC | IDACIO (Biological) | Consulting Fee | Cash or cash equivalent | $59.78 | General |
| Category: Biosimilars | ||||||
| 08/16/2023 | Fresenius Kabi USA, LLC | IDACIO (Biological) | Consulting Fee | Cash or cash equivalent | $42.79 | General |
| Category: Biosimilars | ||||||
| 08/16/2023 | Fresenius Kabi USA, LLC | IDACIO (Biological) | Consulting Fee | Cash or cash equivalent | $40.60 | General |
| Category: Biosimilars | ||||||
| 08/16/2023 | Fresenius Kabi USA, LLC | IDACIO (Biological) | Consulting Fee | Cash or cash equivalent | $9.59 | General |
| Category: Biosimilars | ||||||
| 08/16/2023 | Fresenius Kabi USA, LLC | IDACIO (Biological) | Consulting Fee | Cash or cash equivalent | $5.00 | General |
| Category: Biosimilars | ||||||
| 08/07/2023 | Fresenius Kabi USA, LLC | IDACIO (Biological) | Travel and Lodging | In-kind items and services | $389.77 | General |
| Category: Biosimilars | ||||||
| 08/07/2023 | Fresenius Kabi USA, LLC | IDACIO (Biological) | Travel and Lodging | In-kind items and services | $83.33 | General |
| Category: Biosimilars | ||||||
| 08/01/2023 | Fresenius Kabi USA, LLC | IDACIO (Biological) | Travel and Lodging | In-kind items and services | $195.37 | General |
| Category: Biosimilars | ||||||
| 07/19/2023 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $2,610.00 | General |
| 07/13/2023 | Samsung Bioepis Co., Ltd. | — | Travel and Lodging | Cash or cash equivalent | $10,313.90 | General |
| 07/13/2023 | Samsung Bioepis Co., Ltd. | — | Consulting Fee | Cash or cash equivalent | $5,500.00 | General |
| 07/13/2023 | UCB, Inc. | Bimzelx (Biological) | Travel and Lodging | Cash or cash equivalent | $64.43 | General |
| Category: Immunology | ||||||
| 07/13/2023 | UCB, Inc. | Bimzelx (Biological) | Travel and Lodging | Cash or cash equivalent | $54.70 | General |
| Category: Immunology | ||||||
| 07/07/2023 | UCB, Inc. | — | Consulting Fee | Cash or cash equivalent | $12,780.00 | General |
| 07/06/2023 | Fresenius Kabi USA, LLC | Stimufend (Biological) | Travel and Lodging | In-kind items and services | $512.73 | General |
| Category: Biosimilars | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| BIOSIMILARS I I CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $5,740 | 5 |
| RW TX patterns among patients treated with AMJEVITA in Germany and France. | Amgen Inc. | $4,196 | 1 |
| A Phase 3, Randomized, Double-blind, Placebo and Adalimumab-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in subjects with Active Psoriatic Arthritis Who Are Naive to Biological DMARD Therapy. | Gilead Sciences, Inc. | $1,371 | 8 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 185 | 306 | $128,513 | $19,120 |
| 2022 | 4 | 188 | 389 | $148,018 | $24,482 |
| 2021 | 6 | 243 | 456 | $175,251 | $31,404 |
| 2020 | 7 | 263 | 421 | $144,636 | $22,829 |
Total Patients
879
Total Services
1,572
Medicare Billing
$97,835
Procedure Codes
22
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 114 | 189 | $75,247 | $12,215 | 16.2% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 24 | 50 | $26,400 | $2,166 | 8.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 12 | 15 | $7,660 | $1,625 | 21.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 17 | 34 | $9,360 | $1,558 | 16.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 18 | 18 | $9,846 | $1,556 | 15.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 119 | 256 | $91,904 | $17,540 | 19.1% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2022 | 34 | 68 | $35,970 | $2,736 | 7.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 21 | 47 | $11,468 | $2,110 | 18.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 14 | 18 | $8,676 | $2,096 | 24.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 113 | 244 | $86,521 | $17,579 | 20.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 41 | 79 | $19,006 | $4,085 | 21.5% |
| 20610 | Aspiration and/or injection of large joint or joint capsule | Office | 2021 | 32 | 70 | $36,630 | $3,126 | 8.5% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 28 | 28 | $15,026 | $2,904 | 19.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 16 | 16 | $10,810 | $2,412 | 22.3% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 13 | 19 | $7,258 | $1,298 | 17.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 105 | 202 | $63,832 | $11,305 | 17.7% |
| 20610 | Aspiration and/or injection of large joint or joint capsule | Office | 2020 | 35 | 62 | $32,340 | $2,813 | 8.7% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 31 | 31 | $15,159 | $2,670 | 17.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 43 | 67 | $14,338 | $2,495 | 17.4% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 23 | 32 | $10,544 | $1,953 | 18.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 11 | 11 | $4,719 | $961.54 | 20.4% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 15 | 16 | $3,704 | $631.82 | 17.1% |
About Dr. Jonathan Kay, MD
Dr. Jonathan Kay, MD is a Internal Medicine healthcare provider based in Worcester, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/04/2005. The National Provider Identifier (NPI) number assigned to this provider is 1699766964.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jonathan Kay, MD has received a total of $341,486 in payments from pharmaceutical and medical device companies, with $10,511 received in 2024. These payments were reported across 283 transactions from 28 companies. The most common payment nature is "Consulting Fee" ($229,126).
As a Medicare-enrolled provider, Kay has provided services to 879 Medicare beneficiaries, totaling 1,572 services with total Medicare billing of $97,835. Data is available for 4 years (2020–2023), covering 22 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Rheumatology
- Location Worcester, MA
- Active Since 11/04/2005
- Last Updated 11/17/2020
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1699766964
Products in Payments
- COSENTYX (Biological) $36,029
- Cimzia (Drug) $16,590
- XELJANZ (Drug) $7,918
- Actemra (Biological) $7,419
- INFLECTRA (Biological) $7,300
- IDACIO (Biological) $6,714
- Inflectra (Drug) $6,500
- KRYSTEXXA (Drug) $4,966
- RENFLEXIS (Biological) $4,288
- AMJEVITA (Biological) $4,196
- Inflectra (Biological) $4,008
- RETACRIT (Biological) $3,200
- ABRILADA (Biological) $3,000
- Hyrimoz (Drug) $3,000
- HYRIMOZ (Drug) $2,100
- HADLIMA (Drug) $1,390
- Otezla (Drug) $694.00
- Stimufend (Biological) $512.73
- Humira (Biological) $162.34
- Bimzelx (Biological) $119.13
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Worcester
Leslie Harrold, M.d, M.D
Internal Medicine — Payments: $81,558
Internal Medicine $81,558
Bogdan Nedelescu, M.d, M.D
Internal Medicine — Payments: $50,128
Internal Medicine $50,128
Nikhil Shah, M.d, M.D
Internal Medicine — Payments: $39,924
Internal Medicine $39,924
Dr. Deepa Jagadeesh, M.d, M.D
Internal Medicine — Payments: $37,078
Internal Medicine $37,078
Dr. Julia Andrieni, M.d, M.D
Internal Medicine — Payments: $35,880
Internal Medicine $35,880
Jan Cerny, M.d, M.D
Internal Medicine — Payments: $33,653
Internal Medicine $33,653